C›I›R›B
FOR THE NATIONAL CANCER INSTITUTE

CIRB Approval of Recruitment/Patient Education Materials

Date: October 19, 2021

Study ID: S2013

Study Title: Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Study Chair: Krishna Gunturu, MD

The NCI Cancer Prevention and Control CIRB reviewed S2013 Participant Materials (version 09/30/21) on October 19, 2021 and granted approval. The expedited review was conducted in accordance with the Federally-defined categories of expedited review stated in 45 CFR 46.110(b)(1)(ii) and 21 CFR 56.110(b)(2).

The following documents were reviewed:

1. CIRB Application (PVD 07/21/21)
2. Plain Language Summary (version 09/30/21)
3. Tweets and Graphics (version 09/30/21)

As the Study Chair, you are responsible for reporting all study-related activity and correspondence to the CIRB.

The CIRB complies with the Federal regulations 45 CFR 46, 21 CFR 50, and 21 CFR 56.

If you have any questions regarding this review, please contact the Cancer Prevention and Control CIRB Coordinator at cpccirb@emmes.com.

cc: Mariah Norman,
Diane St. Germain, MS, RN
Lori Minasian, MD, FACP
Linda Parreco, RN, MS
Crystal Miwa
CTSU Protocol Westat
Dana Sparks
Dawn Hershman, MD, BA, MS
Joseph Unger, PhD